Results 111 to 120 of about 61,558 (234)

Generation of Allogeneic CAR‐T Circumvents Functional Deficits in Patient‐Derived Autologous Product for Glioblastoma

International Journal of Cancer, Volume 159, Issue 6, Page 1521-1534, 15 September 2026.
Clinical trials of chimeric antigen receptor T‐cell (CAR‐T) therapies in glioblastoma have shown limited clinical benefits. Whether this may be explained by the basal quality of CAR‐T products, which are currently generated using patient, autologous T‐cells, has been little explored.
Sabra K. Salim, Muhammad Vaseem Shaikh, Jeffrey Wei, William T. Maich, Alisha Anand, Oliver Y. Tang, Minomi K. Subapanditha, Zahra Alizada, Yujin Suk, Manoj Singh, Kui Zhai, Aapti Khanna, Benjamin Brakel, Vassil Dimitrov, Zoya Tabunshchyk, Katie Chan, Kevin R. Brown, Parvez Vora, Donald M. O'Rourke, Zev A. Binder, Chitra Venugopal, Jason Moffat, Sheila K. Singh   +22 more
wiley   +1 more source

Radiological Response to Capecitabine and Temozolomide in an Elderly Patient with Metastatic Leiomyosarcoma: A Case Report. [PDF]

J Clin Med
Yalcin S, Kilinc C, Sahin TK, Dizdar O.
europepmc   +1 more source

Substituent Effects of Heptamethine Cyanine Dyes on Drug Uptake in Patient‐Derived Glioma Cells

ChemMedChem, Volume 21, Issue 17, 14 September 2026.
Glioblastoma (GBM) remains difficult to treat primarily due to tumor heterogeneity and the presence of the blood–brain barrier (BBB). This study demonstrates the in vitro activity of the pan‐kinase inhibitor crizotinib conjugated to BBB‐penetrating heptamethine cyanine dyes with diverse functional groups across four patient‐derived GBM cell lines ...
Carina J. Dumo, Peter J. Choi, Yuge Liu, Osaid Muhammad, Jason A. Correia, Mike Dragunow, Thomas I‐H. Park, Jiney Jose   +7 more
wiley   +1 more source

Estimating Permeabilities from Biased Molecular Dynamics with a Green-Kubo Formalism for Transport across the Blood-Brain Barrier. [PDF]

J Chem Inf Model
Jorgensen C.
europepmc   +1 more source

Rational Use of Herbal Products in Pediatric Patients Treated With Anticancer Drugs in the European Union

Pediatric Blood &Cancer, Volume 73, Issue 9, September 2026.
ABSTRACT Introduction The use of herbal medical preparation (HMP) is rising among pediatric oncology patients, often to manage treatment‐related symptoms. Their effectiveness remains uncertain, and the risk of herb–drug interactions is underestimated.
Orianne Mahot, Mathieu Corvaisier, Laurence Spiesser‐Robelet, Mylène Duplan, Isabelle Pellier, Delphine Bourneau‐Martin, Séverine Derbré   +6 more
wiley   +1 more source

Sequential EGFR inhibition sensitizes glioblastoma to temozolomide. [PDF]

Trends Pharmacol Sci
Yu X, Wu R, Cheng SY.
europepmc   +1 more source

Personalized Zebrafish Models for Fusion‐Positive Pediatric Sarcomas

Pediatric Blood &Cancer, Volume 73, Issue 9, September 2026.
ABSTRACT Clinical sequencing efforts have revolutionized our approaches to categorizing pediatric cancers in real time. This has dramatically improved our ability to profile pediatric tumors, identify actionable vulnerabilities, and influence clinical care.
Lisa H. Hall, Emma N. Harrison, Genevieve C. Kendall   +2 more
wiley   +1 more source

Optimizing the Stupp protocol for treatment of glioblastoma: eliminating age bias, enhancing treatment timing, use of stereotactically-guided sequential boost, and dexamethasone dosing. [PDF]

J Neurooncol
Sharpe MA, Baskin AM, Teh BS, Butler EB, Baskin DS.   +4 more
europepmc   +1 more source

Concurrent Treatment With Lorlatinib and Dinutuximab Beta Induced Acute Gastric Dilation in a Pediatric Patient With Neuroblastoma

Pediatric Blood &Cancer, Volume 73, Issue 10, October 2026.
Suna Lin, Linjie Li, JiJun Chen, Zhaokun Tao, Lifeng Zhang, Junqing Mao, Jinhu Wang   +6 more
wiley   +1 more source

Long‐Term Outcomes of Patients With Relapsed/Refractory Neuroblastoma Treated on ANBL1221: A Report From the Children's Oncology Group

Pediatric Blood &Cancer, Volume 73, Issue 9, September 2026.
ABSTRACT Results of COG ANBL1221 changed treatment paradigms for patients with relapsed/refractory neuroblastoma. Chemoimmunotherapy with irinotecan/temozolomide/dinutuximab is now used as both bridge therapy following suboptimal response to induction and as treatment in first relapse.
Elizabeth Sokol, Arlene Naranjo, Lulu Chen, Rajen Mody, Steven G. DuBois, Rochelle Bagatell, Navin Pinto   +6 more
wiley   +1 more source